Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients’ quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, diff erent treatments have been suggested, ranging from non-steroidal anti-infl ammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specifi c mechanisms and studies of individualised therapies.
Pain in amyotrophic lateral sclerosis
CHIO', Adriano
First
;LAURIA, GIUSEPPE
2017-01-01
Abstract
Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients’ quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, diff erent treatments have been suggested, ranging from non-steroidal anti-infl ammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specifi c mechanisms and studies of individualised therapies.File | Dimensione | Formato | |
---|---|---|---|
D-16-00600 Chio_R4_141116.docx
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
412.58 kB
Formato
Adobe PDF
|
412.58 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
D-16-00600 Chio_R4_141116.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
357.43 kB
Formato
Adobe PDF
|
357.43 kB | Adobe PDF | Visualizza/Apri |
Lancet Neurology 2017.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
225.28 kB
Formato
Adobe PDF
|
225.28 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.